• Wang D, Starr R, Chang WC, Aguilar B, Alizadeh D, Wright SL, Yang X, Brito A, Sarkissian A, Ostberg JR, Li L, Shi Y, Gutova M, Aboody K, Badie B, Forman SJ, Barish ME, Brown CE. Chlorotoxin-directed CAR T cells for specific and effective targeting of glioblastoma. Sci Transl Med. 2020 Mar 4;12(533). DOI: 10.1126/scitranslmed.aaw2672. PubMed PMID: 32132216.
• Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, Aguilar B, Qi Y, Ann DK, Starr R, Urak R, Wang X, Forman SJ, Brown CE. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype. Cancer Immunol Res. 2019 May;7(5):759-772. DOI: 10.1158/2326-6066.CIR-18-0466. Epub 2019 Mar 19. PubMed PMID: 30890531; PubMed Central PMCID: PMC6687561.
• Wang D, Aguilar B, Starr R, Alizadeh D, Brito A, Sarkissian A, Ostberg JR, Forman SJ, Brown CE. Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity. JCI Insight. 2018 May 17;3(10). DOI: 10.1172/jci.insight.99048. eCollection 2018 May 17. PubMed PMID: 29769444; PubMed Central PMCID: PMC6012522.
• Brown CE, Alizadeh D, Starr R, Weng L, Wagner JR, Naranjo A, Ostberg JR, Blanchard MS, Kilpatrick J, Simpson J, Kurien A, Priceman SJ, Wang X, Harshbarger TL, D'Apuzzo M, Ressler JA, Jensen MC, Barish ME, Chen M, Portnow J, Forman SJ, Badie B. Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2016 Dec 29;375(26):2561-9. DOI: 10.1056/NEJMoa1610497. PubMed PMID: 28029927; PubMed Central PMCID: PMC5390684.
• Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain. Clin Cancer Res. 2018 Jan 1;24(1):95-105. DOI: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23. PubMed PMID: 29061641; NIHMSID:NIHMS1619325.

RESEARCH MANUSCRIPTS

• Sahoo P, Yang X, Abler D, Maestrini D, Adhikarla V, Frankhouser D, Cho H, Machuca V, Wang D, Barish M, Gutova M, Branciamore S, Brown CE, Rockne RC. Mathematical deconvolution of CAR T-cell proliferation and exhaustion from real-time killing assay data. J R Soc Interface. 2020 Jan;17(162):20190734. DOI: 10.1098/rsif.2019.0734. Epub 2020 Jan 15. PubMed PMID: 31937234; PubMed Central PMCID: PMC7014796.
• Dixit HG, Starr R, Dundon ML, Pairs PI, Yang X, Zhang Y, Nampe D, Ballas CB, Tsutsui H, Forman SJ, Brown CE, Rao MP. Massively-Parallelized, Deterministic Mechanoporation for Intracellular Delivery. Nano Lett. 2020 Feb 12;20(2):860-867. DOI: 10.1021/acs.nanolett.9b03175. Epub 2019 Oct 28. PubMed PMID: 31647675. Weist MR, Starr R,
• Aguilar B, Shea J, Miles J, Poku E, Gerdts E, Yang X, Pricman S, Forman SJ, Colcher D, Brown CE, Shively J. (2018) Positron emission tomography of adoptively transferred chimeric antigen receptor T cells with Zirconium-89 oxine. J Nucl Med. 59(10): 1531-1537.
• Brown CE, Aguilar B, Starr R, Yang X, Chang WC, Weng L, Chang B, Sarkissian A, Brito A, Sanchez JF, Ostberg JR, D'Apuzzo M, Badie B, Barish ME, Forman SJ. Optimization of IL13Rα2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol Ther. 2018 Jan 3;26(1):31-44. DOI: 10.1016/j.ymthe.2017.10.002. Epub 2017 Oct 5. PubMed PMID: 29103912; PubMed Central PMCID: PMC5763077.
• Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ. Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer. Oncoimmunology. 2018;7(2):e1380764. DOI: 10.1080/2162402X.2017.1380764. eCollection 2018. PubMed PMID: 29308300; PubMed Central PMCID: PMC5749625.
• Keu KV, Witney TH, Yaghoubi S, Rosenberg J, Kurien A, Magnusson R, Williams J, Habte F, Wagner JR, Forman S, Brown C, Allen-Auerbach M, Czernin J, Tang W, Jensen MC, Badie B, Gambhir SS. Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma. Sci Transl Med. 2017 Jan 18;9(373). DOI: 10.1126/scitranslmed.aag2196. PubMed PMID: 28100832; PubMed Central PMCID: PMC5260938.
• Wang X, Popplewell LL, Wagner JR, Naranjo A, Blanchard MS, Mott MR, Norris AP, Wong CW, Urak RZ, Chang WC, Khaled SK, Siddiqi T, Budde LE, Xu J, Chang B, Gidwaney N, Thomas SH, Cooper LJ, Riddell SR, Brown CE, Jensen MC, Forman SJ. Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL. Blood. 2016 Jun 16;127(24):2980-90. DOI: 10.1182/blood-2015-12-686725. Epub 2016 Apr 26. PubMed PMID: 27118452; PubMed Central PMCID: PMC4911862.
• Brown CE, Badie B, Barish ME, Weng L, Ostberg JR, Chang WC, Naranjo A, Starr R, Wagner J, Wright C, Zhai Y, Bading JR, Ressler JA, Portnow J, D'Apuzzo M, Forman SJ, Jensen MC. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma. Clin Cancer Res. 2015 Sep 15;21(18):4062-72. DOI: 10.1158/1078-0432.CCR-15-0428. Epub 2015 Jun 9. PubMed PMID: 26059190; PubMed Central PMCID: PMC4632968.

FIELD REVIEWS

• Brown CE, Mackall CL. CAR T cell therapy: inroads to response and resistance. Nat Rev Immunol. 2019 Feb;19(2):73-74. DOI: 10.1038/s41577-018-0119-y. Review. PubMed PMID: 30631206.
• Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE. CAR T cells for brain tumors: Lessons learned and road ahead. Immunol Rev. 2019 Jul;290(1):60-84. DOI: 10.1111/imr.12773. Review. PubMed PMID: 31355493; PubMed Central PMCID: PMC6771592.

To view more of Christine Brown's publications, please visit Christine Brown's full bibliography